<DOC>
	<DOCNO>NCT00919555</DOCNO>
	<brief_summary>The purpose study determine safety efficacy Tretinoin Pioglitazone HCL patient ALS currently Riluzole .</brief_summary>
	<brief_title>Combination Therapy Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>Physicians Phoenix Neurological Associates ( PNA ) look individual diagnose ALS participate double-blind , placebo control study Tretinoin Pioglitazone HCL , use combination Riluzole , treat ALS . This investigator initiate trial conduct Dr. Todd Levine Dr. David Saperstein help determine whether Tretinoin Pioglitazone HCL , combination , slow progression ALS . At present , little effective therapy ALS , know cause . Therefore tremendous unmet need effective therapy disease physician PNA interested role develop active anti-excitotoxic cocktail patient ALS . Since recent data suggest inflammatory mechanism may interact promote neurodegeneration ( cell spinal cord brain lose ) , number anti-inflammatory treatment strategy evaluate animal model . Some study show mice give Pioglitazone HCL demonstrate improved muscle strength body weight , exhibit delayed disease onset well longer survival rate compare non treated mouse . In addition study , retinoic acid study extensively various model injure nervous system . These study show retinoic acid , Tretinoin may neuroprotective support axonal growth , could turn slow disease progression . The purpose study determine drug `` cocktail '' could offer best chance attain significant reduction disease progression utilize currently available FDA-approved agent</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>El Escorial Classification laboratory support probable , probable , definite ALS Age 18 85 year Male female FVC great equal 70 % predict Patients FVC 1.5 L 70 % predict History liver disease Severe renal failure ( CrCl &lt; 30 ) History coronary artery disease require placement stent , bypass surgery previous myocardial infarction EKG baseline evidence previous myocardial infarction , cardiomyopathy , arrhythmia History intolerance Riluzole , Tretinoin , Pioglitazone HCL History diabetes Any comorbid condition would make completion trial unlikely</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>ALS Treatment</keyword>
	<keyword>Tretinoin</keyword>
	<keyword>Pioglitazone HCL</keyword>
	<keyword>Actos</keyword>
	<keyword>Tau level</keyword>
	<keyword>ALS</keyword>
</DOC>